6 stories found
Longeveron and Vision Marine Technologies both announced plans for a 1-for-10 reverse stock split. These actions are intended to help the companies regain compliance with Nasdaq's minimum bid-price requirements.
Longeveron expects to release data from its ELPIS II trial in August 2026 and is transitioning to an asset-light partnering model for future development.
Longeveron anticipates releasing data from its ELPIS II HLHS study in mid-September, while also confirming its cash runway extends into the fourth quarter of 2026.
HealthEquity announced a Non-GAAP EPS of $0.95, surpassing estimates by $0.05, and revenue of $334.6 million, which also beat expectations by $1.78 million.
Copa Holdings reported strong financial results, with GAAP EPS of $5.16 beating estimates by $1.20 and revenue of $1.05 billion surpassing expectations. Longeveron, however, missed its GAAP EPS target at -$0.19, though its revenue of $0.4 million beat projections.
A significant $30 million investment has been identified as a compelling reason to consider buying shares in the penny stock Longeveron today.